Top 10 Psychedelic Papers on Chronic Pain

The qualitative interview study assessed the efficacy of psilocybin and LSD to treat cluster headaches and found that a single dose was often sufficient to terminate a cluster period and that subhallucinogenic doses were also often reported to be effective treatments. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The open-label study with LSD and DPT for end-of-life anxiety related to terminal cancer found that patients improved on mood/psychological scores. The study also found a non-significant trend towards lower narcotic medication use. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

This double-blind, placebo-controlled, cross-over study found that a medium dose of psilocybin reduced migraines (headaches) in the two weeks after dosing. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The follow-up study of psilocybin-assisted therapy for anxiety and depression, found that it also reduced suicidal ideation (SI) and loss of meaning (LoM) up to the 4. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The case study describes patients from a randomised, double-blind, placebo-controlled trial investigating single-dose psilocybin psychotherapy to treat cancer-related anxiety and depression. These four participants’ personal narratives extended beyond the cancer diagnosis itself, frequently revolving around themes of self-compassion and love, acceptance of death, and memories of past trauma. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The double-blind placebo-controlled study found that psilocybin frequently caused mild to moderate delayed and transient headaches in healthy volunteers in a dose-dependent manner. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

The review synthesises clinical and mechanistic evidence suggesting classic psychedelics — via 5‑HT2A receptor agonism and resultant changes in brain communication between brain networks — may reverse neural alterations underlying chronic pain and produce analgesic effects, with limited but promising reports in cancer pain, phantom limb pain and cluster headache. Given their comparatively favourable safety profile versus opioids, the authors propose further clinical research into psychedelics as non‑opioid analgesics. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone.

The survey study found that indoleamine hallucinogens such as psilocybin and LSD are reportedly comparable to or superior in efficacy against cluster headaches than conventional treatments. Importantly, infrequent and non-hallucinogenic doses of these substances were reported to suffice for this effect to occur. It adds a concrete angle on psychedelics and chronic pain, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.

This open-label, case series study investigated the efficacy of the non-hallucinogenic LSD-analog BOL-148 for treating cluster headaches within a clinically diagnosed patient sample. The results show that three single doses of BOL-148 within 10 days can either break a cluster headache cycle or considerably improve the frequency and intensity of attacks, even resulting in changing from a chronic to an episodic form, with remission extending for many months or longer. For readers, the value is not just the result but the study design: it shows how psychedelics and chronic pain performs when tested under more structured clinical conditions.

The double-blind study compared the efficacy and safety of oral ketamine and diclofenac as treatments of mild to moderate depression over a 6-week treatment period and found that ketamine resulted in significant reductions of depression scores above those achieved by diclofenac. For readers, the value is not just the result but the study design: it shows how psychedelics and chronic pain performs when tested under more structured clinical conditions. Together with the other papers here, it shows how the topic has developed across clinical findings, mechanisms, limitations, and open questions.